ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy

Investigator: Jorge Darcourt, MD

Study Coordinator: Erick Villarreal-Williams

Status: Enrolling Number: NCT02531516

Phone: 713.441.9775

IRB Number: Pro00013873


The purpose of this study is to determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy results in an improvement of metastasis-free survival.
More to Explore